Effect of bergamottin and prototypical inducers on mRNA in primary cultures of human hepatocytes
| Compound | CYP1A1 | CYP1A2 | CYP3A4 | CYP2B6 | UDPGT1A |
|---|---|---|---|---|---|
| Rifampicin | N.C. | N.C. | 22.7 ± 5.6 | 6.1 ± 1 | N.C. |
| β-NF | 34 ± 8 | 19 ± 4 | N.C. | N.C. | 4.4 ± 0.5 |
| 3MC | 53 ± 8 | 16 ± 3 | N.C. | N.C. | 4.6 ± 0.5 |
| Phenobarbital | N.C. | N.C. | 8.4 ± 0.7 | 14.4 ± 3.3 | 3.5 ± 0.4 |
| Bergamottin | 53.3 ± 8 | 12 ± 1.4 | 7.8 ± 4 | 11.2 ± 1.5 | 5 ± 0.2 |
Primary human hepatocytes were treated for 48 h with 0.1% DMSO (control), rifampicin (50 μM) or β-NF (50 μM), 3MC (8 μM) or PB (2 mM), or bergamottin (5 μM) for 48 h. At the end of these treatments, the culture medium was discarded, RNA extracted, reverse transcribed, and fluorescently labeled microarray analysis was conducted as described under Materials and Methods. Each sample was analyzed in quadruplicate. Values represent fold increase over control. Each value represents the mean ± S.D.
N.C., no change.